期刊
AMERICAN JOURNAL OF PATHOLOGY
卷 181, 期 3, 页码 978-992出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2012.06.007
关键词
-
类别
资金
- National Health and Medical Research Council of Australia [454723]
- Career Development Award Fellowship
- Transport Accident Commission
- NIH [1R43CA132395-01A2]
- Victorian State Government's Department of Innovation, Industry, and Regional Development
- Australian government (AusAID)
- State Government of Victoria
- Australian government
Evidence suggests a proinflammatory role of lysophosphatidic acid (LPA) in various pathologic abnormalities, including in the central nervous system. Herein, we describe LPA as an important mediator of inflammation after spinal cord injury (SCI) in zebrafish and mice. Furthermore, we describe a novel monoclonal blocking antibody raised against LPA that potently inhibits LPA's effect in vitro and in vivo. This antibody, B3, specifically binds LPA, prevents it from interacting with its complement of receptors, and blocks LPA's effects on the neuronal differentiation of human neural stem/progenitor cells, demonstrating its specificity toward LPA signaling. When administered systemically to mice subjected to SCI, B3 substantially reduced glial inflammation and neuronal death. B3-treated animals demonstrated significantly more neuronal survival upstream of the lesion site, with some functional improvement. This study describes the use of anti-LPA monoclonal antibody as a novel therapeutic approach for the treatment of SCI. (Am J Pathol 2012, 181:978-992; http://dx.doi.org/10.1016/j.ajpath.2012.06.007)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据